KellyEliseDooleyMD

Professor of Medicine, Vanderbilt University Medical Center

Dr. Dooley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1161 21st Avenue South, A2200 MCN
Nashville, TN 37232
Phone+1 615-322-8972

Kelly Dooley, MD is a healthcare professional specialized in Infectious Diseases and based in Nashville, TN. Her education included a Fellowship in Infectious Diseases and Residency in Internal Medicine at Johns Hopkins University after graduating from Duke University School of Medicine. Dr. Dooley has experience in emerging infectious diseases and has published in a number of respected journals on topics related to infectious diseases, particularly tuberculosis and HIV. Her work in clinical trials reflects her focus on the study and treatment of tuberculosis.

PubMed

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients.
Thanakorn Vongjarudech, Anne-Gaëlle Dosne, Bart Remmerie, Kelly E Dooley, James C M Brust
International Journal of Antimicrobial Agents. 2025-04-01
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy.
Ahizechukwu C Eke, Sean S Brummel, Muktar H Aliyu, Lynda Stranix-Chibanda, George U Eleje
Clinical Infectious Diseases. 2025-03-17
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous analysis of isoniazid and pyrazinamide in cerebrospinal fluid.
Sydwell Poulo Maputla, Anton Joubert, Sandra Castel, Marthinus van der Merwe, Edda Zangenberg
Journal of Pharmaceutical and Biomedical Analysis. 2025-03-15

Journal Articles

State of the Art Review of HIV‐TB Coinfection in Special Populations
Ethel D Weld, Kelly E Dooley, Clinical Pharmacology & Therapeutics

VUMC’s Kelly Dooley Joins Clinical Pharmacology BoardJanuary 13th, 2025
Johns Hopkins School of Medicine Among Clinical Trial Sites Testing COVID-19 TherapiesNovember 18th, 2020
Johns Hopkins Researchers to Present Latest Findings on TB and HIV at CROI 2019March 7th, 2019
Join now to see all

Short-course rifapentine for TB prevention for all: clinical pharmacology mattersVANDERBILT UNIVERSITY MEDICAL CENTER2024–2029
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchVANDERBILT UNIVERSITY MEDICAL CENTER2020–2026
Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV)VANDERBILT UNIVERSITY MEDICAL CENTER2023–2025
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
PK/PD Issues In The Use Of New Therapies For The Treatment Of TuberculosisNational Institute Of Allergy And Infectious Diseases2009–2012